B
B. Åblad
Publications - 9
Citations - 609
B. Åblad is an academic researcher. The author has contributed to research in topics: Heart failure & Pimobendan. The author has an hindex of 8, co-authored 8 publications receiving 555 citations.
Papers
More filters
Journal ArticleDOI
Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
Jens Häggström,Adrian Boswood,Michael R. O'Grady,Olaf Jöns,Sarah Smith,Simon Swift,M. Borgarelli,B. Gavaghan,Jan-Gerd Kresken,M. Patteson,B. Åblad,Claudio Bussadori,Tony M. Glaus,A. Kovacevic,M. Rapp,Roberto A. Santilli,Anna Tidholm,A. Eriksson,M.C. Belanger,M. Deinert,C.J.L. Little,Clarence Kvart,Anne French,M. Ronn-Landbo,Gerhard Wess,A.V. Eggertsdottir,M.L. O'Sullivan,Matthias Schneider,Christophe W. Lombard,Joanna Dukes-McEwan,Ruth Willis,A. Louvet,Rocky DiFruscia +32 more
TL;DR: Pimobendan plus conventional therapy prolongs time to sudden death, euthanasia for cardiac reasons, or treatment failure in dogs with CHF caused by MMVD compared with benazeprilplus conventional therapy.
Journal ArticleDOI
Efficacy of Enalapril for Prevention of Congestive Heart Failure in Dogs with Myxomatous Valve Disease and Asymptomatic Mitral Regurgitation
Clarence Kvart,Jens Häggström,Henrik D. Pedersen,Kerstin Hansson,A. Eriksson,Anna-Kaisa Järvinen,Anna Tidholm,Karina Bsenko,Erik O. Ahlgren,Mikael Ilves,B. Åblad,T. Falk,Ellen Bjerkfås,Susanne Gundler,Peter Lord,Gudrun Wegeland,Eva Adolfsson,Jens Corfitzen +17 more
TL;DR: Long-term treatment with enalapril in asymptomatic dogs with MVD and MR did not delay the onset of heart failure regardless of whether or not cardiomegaly was present at initiation of the study.
Journal ArticleDOI
Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving Pimobendan or Benazepril: the QUEST study
Jens Häggström,Adrian Boswood,Michael R. O'Grady,Olaf Jöns,Sarah Smith,Simon Swift,M. Borgarelli,B. Gavaghan,Jan-Gerd Kresken,M. Patteson,B. Åblad,Claudio Bussadori,Toni M Glaus,A. Kovacevic,M. Rapp,Roberto A. Santilli,Anna Tidholm,A. Eriksson,M.C. Belanger,M. Deinert,C.J.L. Little,Clarence Kvart,Anne French,M. Ronn-Landbo,Gerhard Wess,A.V. Eggertsdottir,M. Lynne O'Sullivan,Matthias Schneider,Christophe W. Lombard,Joanna Dukes-McEwan,Ruth Willis,A. Louvet,Rocky DiFruscia +32 more
TL;DR: Pimobendan versus benazepril resulted in similar QoL during the study, but conferred increased time before intensification of CHF treatment.
Journal ArticleDOI
Heart Rate, Heart Rate Variability, and Arrhythmias in Dogs with Myxomatous Mitral Valve Disease
C.E. Rasmussen,T. Falk,Nora E. Zois,S.G. Moesgaard,Jens Häggström,H. D. Pedersen,B. Åblad,H.Y. Nilsen,Lisbeth H. Olsen +8 more
TL;DR: Holter-derived variables can identify MMVD severity in Cavalier King Charles Spaniels (CKCS) and distinguish CKCS with moderate or severe mitral regurgitation from CKCS in CHF in specific intervals and "Premature normals" and TI showed diagnostic potential.
Journal ArticleDOI
Radial and longitudinal strain and strain rate assessed by speckle-tracking echocardiography in dogs with myxomatous mitral valve disease.
Nora E. Zois,Anna Tidholm,K.M. Nägga,S.G. Moesgaard,C.E. Rasmussen,T. Falk,Jens Häggström,H. D. Pedersen,B. Åblad,H.Y. Nilsen,Lisbeth H. Olsen +10 more
TL;DR: Assessed by STE, LV function appeared to be augmented in moderate-to-severe disease, however, at CHF stages with greatly enlarged atria, a decrease to levels comparable to dogs with no or minimal MR was observed.